Swotting effective hypertension therapy: Ramipril versus telmisartan

Saroj Prasad Shah, Gourab Prasad Borah, Karun Bhatti, Rina Das, Dinesh Kumar Mehta

M M College of Pharmacy, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, Haryana, India.

Refer this article

Saroj Prasad Shah, Gourab Prasad Borah, Karun Bhatti, Rina Das, Dinesh Kumar Mehta, 2023. Swotting effective hypertension therapy: ramipril versus telmisartan. Journal of medical pharmaceutical and allied sciences, V 12 - I 1, Pages - 5532 – 5539. DOI: 10.55522/jmpas.V12I1.4280.

ABSTRACT

One of the most important, globally controllable risk factors for cardiovascular diseases and early mortality is hypertension. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, both of which inhibit the renin-angiotensin system, are becoming more common as initial treatments for the management of hypertension patients with which ramipril and telmisartan being the most frequently used. Telmisartan has the highest affinity for the AT1 receptor of all the ARBs.Ramipril and telmisartan both are found to provide a variety of therapeutic advantages. In this study, a detailed comparative analysis has been done between ramipril and telmisartan regarding their efficacy, safety, monotherapy as well as combination therapy outcome and measures to be taken while considering both drugs. This study focused on which one is more successful in treating hypertension individuals, while also having a superior safety profile and combining the two medications which one is linked to more side effects, additional benefits, or other important information to eliminate the hazards connected to blood pressure increase while minimizing negative effects on quality of life.

Keywords:

Hypertension Therapy, Ramipril, Telmisartan, Monotherapy, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blocker,

Full Text Article